NCT04033926View on ClinicalTrials.gov

A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

January 14, 2020

Primary Completion Date

April 6, 2022

Study Completion Date

April 6, 2022

Conditions
PolymyositisDermatomyositis
Interventions
DRUG

KZR-616

Subcutaneous 30 mg weekly for 2 weeks, then 45 mg weekly for 14 weeks

DRUG

Placebo

Subcutaneous injection for 16 weeks

Trial Locations (14)

11021

KZR Research Site, Great Neck

15213

KZR Research Site, Pittsburgh

16635

KZR Research Site, Duncansville

21224

KZR Research Site, Baltimore

23233

KZR Research Site, Henrico

30322

KZR Research Site, Atlanta

33136

KZR Research Site, Miami

48109

KZR Research Site, Ann Arbor

66160

KZR Research Site, Kansas City

78756

KZR Research Site, Austin

90211

KZR Research Site, Beverly Hills

92868

KZR Research Site, Orange

Unknown

KZR Research Site, Prague

KZR Research Site, Göttingen

Sponsors
All Listed Sponsors
lead

Kezar Life Sciences, Inc.

INDUSTRY

NCT04033926 - A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis | Biotech Hunter | Biotech Hunter